IRIS
ALFIERI, Roberta
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.349
AS - Asia 7.310
EU - Europa 6.853
SA - Sud America 1.137
AF - Africa 379
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 5
Totale 25.040
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.145
SG - Singapore 3.008
CN - Cina 2.501
IT - Italia 1.372
IE - Irlanda 1.105
FI - Finlandia 1.072
BR - Brasile 943
SE - Svezia 935
DE - Germania 726
HK - Hong Kong 558
UA - Ucraina 484
VN - Vietnam 424
NL - Olanda 287
TR - Turchia 271
ZA - Sudafrica 236
GB - Regno Unito 180
RU - Federazione Russa 164
IN - India 162
FR - Francia 146
CA - Canada 133
AT - Austria 95
BE - Belgio 84
AR - Argentina 82
CI - Costa d'Avorio 73
BD - Bangladesh 60
PL - Polonia 50
ID - Indonesia 47
JP - Giappone 47
MX - Messico 46
IQ - Iraq 36
ES - Italia 34
EC - Ecuador 32
CZ - Repubblica Ceca 31
KR - Corea 29
PK - Pakistan 27
CO - Colombia 22
LT - Lituania 21
MA - Marocco 21
UZ - Uzbekistan 21
IR - Iran 18
VE - Venezuela 15
TN - Tunisia 13
PY - Paraguay 12
AZ - Azerbaigian 11
KE - Kenya 11
AL - Albania 10
CL - Cile 9
JO - Giordania 9
RO - Romania 9
EG - Egitto 8
HU - Ungheria 8
PS - Palestinian Territory 8
UY - Uruguay 8
PE - Perù 7
AE - Emirati Arabi Uniti 6
BO - Bolivia 6
EE - Estonia 6
KG - Kirghizistan 6
KZ - Kazakistan 6
LB - Libano 6
LU - Lussemburgo 6
NP - Nepal 6
SA - Arabia Saudita 6
CH - Svizzera 5
CR - Costa Rica 5
JM - Giamaica 5
DZ - Algeria 4
HN - Honduras 4
IL - Israele 4
MY - Malesia 4
NZ - Nuova Zelanda 4
SY - Repubblica araba siriana 4
AM - Armenia 3
AO - Angola 3
AU - Australia 3
DK - Danimarca 3
DO - Repubblica Dominicana 3
GE - Georgia 3
LV - Lettonia 3
MD - Moldavia 3
PA - Panama 3
QA - Qatar 3
SN - Senegal 3
XK - ???statistics.table.value.countryCode.XK??? 3
BB - Barbados 2
BG - Bulgaria 2
BH - Bahrain 2
BW - Botswana 2
CY - Cipro 2
EU - Europa 2
LK - Sri Lanka 2
OM - Oman 2
RS - Serbia 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
TJ - Tagikistan 2
TW - Taiwan 2
AD - Andorra 1
BY - Bielorussia 1
CG - Congo 1
Totale 25.024
Salva come PNG Salva come JPEG
Città #
Singapore 1.567
Dublin 1.103
Chandler 1.038
Ashburn 1.012
Dallas 940
Beijing 635
Santa Clara 629
Jacksonville 560
Hong Kong 551
Ann Arbor 508
Parma 471
Dearborn 397
Boardman 346
Nanjing 251
Izmir 233
New York 228
Johannesburg 227
Shanghai 227
Munich 197
Princeton 196
Los Angeles 191
San Mateo 169
Ho Chi Minh City 159
Hefei 141
Bremen 135
Wilmington 115
Helsinki 106
Milan 98
Nanchang 92
São Paulo 89
Kunming 88
Chicago 87
Hanoi 84
Moscow 83
Shenyang 82
Vienna 78
Jinan 75
Hebei 74
Abidjan 73
Buffalo 72
Toronto 72
Woodbridge 68
Brussels 66
Des Moines 66
Marseille 56
Tianjin 56
Columbus 47
Seattle 47
Pune 46
Turku 46
Guangzhou 44
Houston 42
Jiaxing 42
Amsterdam 40
Changsha 40
Warsaw 39
Bologna 38
Brooklyn 36
Frankfurt am Main 36
London 36
The Dalles 36
Modena 34
Rio de Janeiro 34
Council Bluffs 33
Jakarta 33
Tokyo 33
Denver 31
Düsseldorf 30
Stockholm 30
Hangzhou 27
Seoul 27
Norwalk 26
San Jose 25
Phoenix 24
Reggio Emilia 24
Rome 24
Brasília 23
Haiphong 23
Manchester 23
Redmond 23
Belo Horizonte 22
Leawood 22
Nuremberg 22
Montreal 21
Curitiba 20
Fremont 20
San Francisco 20
Tashkent 20
Zhengzhou 20
Campinas 19
Poplar 19
Chennai 18
Augusta 16
Boston 16
Dhaka 16
Atlanta 15
Bari 15
Brno 15
Wuhan 15
Ankara 14
Totale 15.298
Salva come PNG Salva come JPEG
Nome #
Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR 313
A New ABCB1 Inhibitor Enhances the Anticancer Effect of Doxorubicin in Both In Vitro and In Vivo Models of NSCLC 228
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 222
Efficacy of the cdk4/6 dual inhibitor abemaciclib in egfr-mutated nsclc cell lines with different resistance mechanisms to osimertinib 207
PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC) 206
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models 204
Irreversible Inhibition of Epidermal Growth Factor Receptor Activity by 3-Aminopropanamides. 192
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. 186
Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer 181
Dual inhibition of CDK4/6 and PI3K/AKT/mTOR signaling impairs energy metabolism in MPM cancer cells 179
Cell size reduction induced by inhibition of the mTOR/S6K signaling pathway protects Jurkat cells from apoptosis 172
MESENCHYMAL STROMAL CELLS ISOLATED FROM DEFINED NSCLC CONTEXTURES REPRODUCE THE IMMUNE SIGNATURE OF THE PARENTAL MICROENVIRONMENT 171
Allotrapianto di polmone sinistro nel coniglio.Modello sperimentale per lo studio della conservazione del polmone. 171
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC 170
Synthesis of Fe3O4 superparamagnetic nanoparticles and anchoring via ‘click’ chemistry to SiC/SiO2 nanowires for radiofrequency magnetic field hyperthermia 165
Targeting PI3K somatic mutations reduces invasion and EMT in squamous cell carcinoma of the lung 165
Characterization of gefitinib uptake in NSCLC cell lines 164
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. 164
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells. 164
5-Benzylidene-hydantoins: synthesis and antiproliferative activity on A549 lung cancer cell line 163
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance 162
Compatible osmolytes modulate the response of porcine endothelial cells to hypertonicity and protect them from apoptosis 160
5-Benzylidene-hydantoins as new EGFR inhibitors with antiproliferative activity 160
Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion 160
A sulfonyl fluoride derivative inhibits EGFR L858R/T790M/C797S by covalent modification of the catalytic lysine 160
Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell line 158
Afatinib therapy in case of EGFR G724S emergence as resistance mechanism to osimertinib 158
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer 157
Isolation and Characterization of Circulating Tumor Cells in Squamous Cell Carcinoma of the Lung Using a Non-EpCAM-Based Capture Method 156
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation 156
A three-fold novel nanosystem made by SiC/SiO2 core/shell nanowires functionalized with magnetic nanoparticles and substituted porphyrin for nanomedicine applications 156
Low PD-1 expression in Cytotoxic CD8+ Tumor infiltrating Lymphocytes Confers an Immune Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value 155
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations. 153
Antiproliferative and proapototic effects of a new combi-molecule on non small cell lung cancer cell lines 152
Creatine as a compatible osmolyte in muscle cells exposed to hypertonic stress 150
Effect of specific PI3K/mTOR inhibitors in squamous lung cancer cells carrying PI3K alterations 149
Effect of inducible FHIT and p53 expression in the Calu-1 lung cancer cell line 149
CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells 149
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines 148
Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification 148
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines 147
Anti-proliferative effect of combining Letrozole with Sorafenib in MCF-7/Arom-1 breast cancer cells 147
Anti-proliferative effect of letrozole and sorafenib in MCF-7/AROM-1 breast cancer cells 146
Antitumoral effect of a nanotechnology-based photodynamic therapy. 146
Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments 146
Methodology for the assessment of lung protection. Human pulmonary artery endothelial cell preservation using haemaccel. 144
5-benzylidene-hydantoins as new inhibitors of cell proliferation 144
Cytocompatibility and Cellular Internalization Mechanisms of SiC/SiO2 Nanowires 144
Attenuated expression of 70kDa heat shock protein in WI-38 human fibroblasts during aging in vitro 141
Induction of BGT-1 and amino acid system A transport activities in endothelial cells exposed to hyperosmolarity 141
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines 141
Erlotinib enhances antibody-dependent cellular cytotoxicity of wil-type erlotinib-sensitive NSCLC cell lines 140
CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells 139
SiC/SiO2/M-NP core/shell nanowires functionalized with fluorinated porphyrins 138
Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN 138
Attenuata induzione del gene SNAT-2 in fibroblasti umani senescenti esposti a stress iperosmolare 136
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion 136
5-benzylidene-hydantoin UPR 1024 acts as EGFR inhibitor and induces DNA damage in A549 NSCLC cell line 136
An original application of plasma expanders: heart-lung preservation. 136
Isolation and characterization of H23 clones resistant to the KRASG12C inhibitors sotorasib and adagrasib 135
Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines 135
Gefitinib metabolism by CYP1A1 affects biological responses in NSCLC cell lines. 134
Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer 134
Corrigendum: CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells (Frontiers in Oncology, (2022), 12, (942341), 10.3389/fonc.2022.942341) 134
Aberrant expression of PTEN in squamous lung cancer cells: molecular analysis and impact on the synergistic combination of the targeted therapy with BKM120 and Defactinib 133
CDK4/6 inhibitors overcome resistance to osimertinib in NSCLC cell lines independently from resistance mechanisms 133
Lung mesenchymal cells function as an inductive microenvironment for human lung cancer propagating cells† 133
Effects of FGFR1 inhibition on survival, proliferation, and energy metabolism in Non Small Cell Lung Cancer (NSCLC) cell lines 132
Drug-induced cellular death dynamics monitored by a highly sensitive organic electrochemical system 132
An effective solution for prolonged preservation of cultured human pulmonary artery endothelial cells 130
) Sperimentazione su pneumociti di tipo II per la conservazione del polmone in funzione del trapianto. Soluzioni idroelettrolitiche a confronto. 130
Osmotic regulation of ATA2 mRNA expression and amino acid transport system A activity 130
Identification and tumorigenic role of Mesenchymal Stem Cells from human lung cancer 130
SiO2/SiC core-shell nanowires for nanomedicine applications 130
CDK4/6 INHIBITORS AS A NEW THERAPEUTIC APPROACH IN MESOTHELIOMA MODELS 129
Epidermal Growth Factor Receptor Irreversible Inhibitors: Chemical Exploration of the Cysteine-Trap Portion 129
Clinical perspective for irreversible tyrosine kinase inhibitors in cancer 129
New MDR1 inhibitors for overcoming multidrug resistance 129
Anti-proliferative and pro-apoptotic effects of Sorafenib in breast cancer cells in vitro. 129
Coordinated inducible expression of p53 and FHIT has a strong anti proliferative effect in Calu-1 lung cancer cell line. 128
155P Antitumoral efficacy of dual blockade of EGFR signaling by osimertinib in combination with selumetinib or cetuximab in activated EGFR human NSCLC tumor models 126
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. (Cavazzoni and Bonelli co-first authors) 126
A new extracellular type solution for lung preservation: "in vitro" comparison with Beltzer, low potassium Dextran and Euro-Collins solutions by means of human lung fibroblasts. 125
New strategies to overcome resistance to EGFR tyrosine kinase inhibitors in non small cell lung cancer 125
Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies 124
Alterazioni della degradazione proteasoma-dipendente nel corso dell'invecchiamento ed effetti delle restrizioni caloriche 123
New treatment opportunities in phosphatase and tensin homolo(PTen)-deficient tumors: Focus on PTen/focal adhesion kinase pathway 123
INCREASED SOLUBLE AND MEMBRANE-BOUND PD-L1 EXPRESSION IN NSCLC CELL LINES TREATED WITH PEMETREXED 123
Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: review of the literature and future perspectives 123
5'-Untranslated region of heat shock protein 70 mRNA drives translation under hypertonic conditions 123
Cytocompatible 3C-SiC/SiO2 core shell nanowires for bimodal cancer therapy 122
Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility 122
MYC Amplification as a Potential Mechanism of Primary Resistance to Crizotinib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report 122
Anti-proliferative and pro-apoptotic effects of soarfenib in MCF-7/AROM-1 breast cancer cells. 121
Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines 121
SiO2/SiC core-shell nanowires for nanomedicine applications 120
Roles of compatible osmolytes and heat shock protein 70 in the induction of tolerance to stresses in porcine endothelial cells 118
The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells 118
Activation of heat-shock transcription factor 1 by hypertonic shock in 3T3 cells 117
Role of sphingolipid metabolism in osimertinib-resistance in EGFR-mutated NSCLC models 116
Totale 14.765
Salva come PNG Salva come JPEG
Categoria #
all - tutte 89.268
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 89.268
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021846 0 0 0 0 0 24 128 53 244 49 287 61
2021/20221.011 44 22 52 65 34 14 135 119 60 71 67 328
2022/20234.206 399 434 276 278 414 466 44 297 1.364 25 169 40
2023/20241.762 86 139 60 64 157 403 129 131 68 88 155 282
2024/20255.391 177 281 345 406 496 566 305 223 737 463 472 920
2025/20266.633 1.026 1.078 1.418 1.061 1.562 488 0 0 0 0 0 0
Totale 25.372